VYGLEA — 2266135

Application number
2266135

Registration number
TMA1364990

Type(s)
Standard Characters

Category
Trademark

CIPO Status
REGISTERED

TM5 status
LIVE/REGISTRATION/Issued and Active

The trademark application has been registered with the Office.

Filed
2023-06-27

Registered
2025-12-05

Registration Expiry Date
2035-12-05

Registered Owner
Biohaven Therapeutics Ltd.
Road Town
Ritter House, P.O. Box 173
Tortola, VG1110
VIRGIN ISLANDS (BRITISH)

Agent
SMART & BIGGAR LP
Scotia Plaza, 40 King Street West
40th Floor
Toronto
ONTARIO M5H3Y2

Documents
View documents

Index headings

VYGLEA

Goods (Nice class & Statement)

5	(1) Medicated and pharmaceutical preparations, both prescription and over-the-counter, for the treatment of central nervous system disorders, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, epilepsy, neurologic illnesses in the nature of brain injury, spinal cord injury, seizure disorders, and psychiatric illnesses in the nature of anxiety disorder, depression, Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Schizophrenia, Eating Disorders, disruptive behaviour, dissocial disorders, Neurodevelopmental disorders, for the treatment of brain ischemia, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome, for the treatment of neurodegenerative diseases, in the nature of Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis, for the treatment of pain, in the nature of opioid sparing analgesia, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma, for the treatments of degenerative diseases, in the nature of breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia, for the treatment of neuropsychiatric disorders, in the nature of treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia, for the treatment of cancer, for the treatment of cerebellar disorders, in the nature of spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor, for the treatment of brain and cord injuries, in the nature of post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury, for the

treatment of optic and retinal neuropathies, in the nature of glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies, for the treatment of headache and facial pain, in the nature of headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia, for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes.

Action History

Action	Action date	Due date	Comments
Filed	2023-06-27		
Created	2023-06-27		
Formalized	2023-06-27		
Pre-Assessment Letter Sent	2023-07-13		Goods or Services Not Acceptable
Agent Name Changed	2024-02-28		
Agent Name Changed	2024-02-28		
Search Recorded	2024-11-12		
Examiner's First Report	2024-11-12	2025-05-12	
Approval Notice Sent	2025-07-09		APPROVED BY PROGRAM EX200M1
Approved	2025-07-09		APPROVED BY PROGRAM EX200M1
Advertised	2025-09-17		Vol.72 Issue 3699
Registration Pending	2025-12-05		
Registered	2025-12-05	2035-12-05	
Agent Changed	2026-04-21		Transferred From: 5784 To: 59